62,129 Shares in Certara, Inc. (NASDAQ:CERT) Acquired by Algert Global LLC

Algert Global LLC bought a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 62,129 shares of the company's stock, valued at approximately $662,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC grew its position in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. bought a new position in shares of Certara in the fourth quarter worth approximately $47,000. Blue Trust Inc. raised its stake in Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after purchasing an additional 822 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its position in Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock valued at $58,000 after purchasing an additional 3,656 shares during the last quarter. Institutional investors own 73.96% of the company's stock.

Certara Stock Up 1.2%

CERT traded up $0.15 on Friday, hitting $11.77. The company had a trading volume of 211,509 shares, compared to its average volume of 1,302,358. The stock has a fifty day simple moving average of $11.70 and a 200-day simple moving average of $11.71. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market capitalization of $1.91 billion, a P/E ratio of -58.78, a P/E/G ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $17.76.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. During the same quarter in the prior year, the company earned $0.10 earnings per share. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. JMP Securities reiterated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Stephens reissued an "overweight" rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Finally, Robert W. Baird boosted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.